Drug Profile
ACV 1
Alternative Names: ACV-1; AVC 6.8; Vc1.1Latest Information Update: 17 Jun 2016
Price :
$50
*
At a glance
- Originator University of Melbourne
- Developer Calzada; Metabolic Pharmaceuticals
- Class Analgesics; Conotoxins
- Mechanism of Action Cholinergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Neuropathic pain; Postherpetic neuralgia
Most Recent Events
- 02 Oct 2006 Metabolic has initiated enrolment in a phase IIa trial for Neuropathic Sciatic Pain in Australia
- 28 Sep 2006 Phase-II clinical trials in Neuropathic pain in Australia (SC)
- 25 May 2004 Preclinical trials in Pain in Australia (SC)